Publication | Closed Access

Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation

InflammationThrombosisThrombopoiesisBlood PlateletImmunologyHematologyPharmacologyHemostasisFibrinolysisCoagulopathyEculizumab Therapy ResultsMedicineThrombin GenerationMicroparticle Formation